Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OMS 527

Next Previous
Drug Profile

OMS 527

Alternative Names: OMS-182399; OMS527; PDE7 inhibitor - Omeros; Type 7 cyclic nucleotide phosphodiesterase inhibitor - Omeros

Latest Information Update: 17 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asubio Pharma
  • Developer National Institute of Drug Abuse; Omeros Corporation; The Parkinsons Institute and Clinical Center
  • Class Antiparkinsonians; Drug withdrawal therapies; Small molecules
  • Mechanism of Action Type 7 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Impulse control disorders; Movement disorders; Substance-related disorders

Most Recent Events

  • 14 Apr 2023 Omeros Corporation plans a Clinical trial for Cocaine related disorders
  • 10 Apr 2023 Omeros Corporation plans a preclinical study in Cocaine related disorders
  • 15 Feb 2023 Omeros Corporation has multiple patent protection for OMS 527 in USA and world-wide before February 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top